Generic Name and Formulations:
Cholestyramine resin (as Cl) 4g; per 9g packet or scoop.
Various generic manufacturers
Indications for Cholestyramine:
Hypercholesterolemia alone or with hypertriglyceridemia resistant to dietary management. Reduction in risk of coronary heart disease. Pruritus due to partial biliary obstruction.
Initially 1 packet or scoop mixed with fluid or food 1–2 times daily. Maintenance: 2–4 packets or scoops divided into 2 doses; max 6 packets or scoops daily. Increase at 4 week intervals.
See full labeling.
Complete biliary obstruction.
Obtain baseline serum cholesterol, LDL-C, and triglycerides, and monitor during therapy. May need Vit. A, D, K, and folic acid supplementation with long-term therapy. Exclude secondary causes of hypercholesterolemia (e.g., hypothyroidism, diabetes, nephrotic syndrome, dysproteinemias, obstructive liver disease, alcoholism). Favorable trend in cholesterol reduction usually occurs within 1 month; continue therapy to sustain reduction. Phenylketonuria (Light formulation). Constipation. Hemorrhoids. Pregnancy. Nursing mothers.
Inhibits absorption of phenylbutazone, warfarin, chlorothiazide, propranolol, tetracycline, penicillin G, phenobarbital, thyroid drugs, digitalis, many others; give other drugs 1–2 hours before or 4–6 hours after. Additive effects with HMG-CoA reductase inhibitors, nicotinic acid.
Bile acid sequestrant.
Constipation, fecal impaction, aggravation of hemorrhoids, GI disturbances, osteoporosis, Vit. A, D, K, or folic acid deficiencies, increased bleeding, hyperchloremic acidosis, rash, oral or anal irritation.
Formerly known under the brand name Questran.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|